EE05210B1 - Suhkurt?vevastane preparaat ja selle kasutamine meditsiinis - Google Patents

Suhkurt?vevastane preparaat ja selle kasutamine meditsiinis

Info

Publication number
EE05210B1
EE05210B1 EEP200200241A EEP200200241A EE05210B1 EE 05210 B1 EE05210 B1 EE 05210B1 EE P200200241 A EEP200200241 A EE P200200241A EE P200200241 A EEP200200241 A EE P200200241A EE 05210 B1 EE05210 B1 EE 05210B1
Authority
EE
Estonia
Prior art keywords
medicine
antidiabetic agent
antidiabetic
agent
Prior art date
Application number
EEP200200241A
Other languages
English (en)
Estonian (et)
Inventor
Anne Piper Beth
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23716278&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EE05210(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of EE200200241A publication Critical patent/EE200200241A/xx
Publication of EE05210B1 publication Critical patent/EE05210B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
EEP200200241A 1999-11-03 2000-10-13 Suhkurt?vevastane preparaat ja selle kasutamine meditsiinis EE05210B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/432,465 US6586438B2 (en) 1999-11-03 1999-11-03 Antidiabetic formulation and method
PCT/US2000/028467 WO2001032158A2 (fr) 1999-11-03 2000-10-13 Preparation antidiabetique et methode associee

Publications (2)

Publication Number Publication Date
EE200200241A EE200200241A (et) 2003-12-15
EE05210B1 true EE05210B1 (et) 2009-10-15

Family

ID=23716278

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200200241A EE05210B1 (et) 1999-11-03 2000-10-13 Suhkurt?vevastane preparaat ja selle kasutamine meditsiinis

Country Status (34)

Country Link
US (2) US6586438B2 (fr)
EP (1) EP1253944A2 (fr)
JP (2) JP2003529551A (fr)
KR (2) KR100769786B1 (fr)
CN (3) CN101273981B (fr)
AR (1) AR026355A1 (fr)
AU (1) AU781781B2 (fr)
BG (2) BG106732A (fr)
BR (1) BR0015295A (fr)
CA (1) CA2389931A1 (fr)
CZ (2) CZ304090B6 (fr)
DE (1) DE60038455T2 (fr)
EE (1) EE05210B1 (fr)
ES (1) ES2302702T3 (fr)
GE (2) GEP20053539B (fr)
HK (1) HK1045655A1 (fr)
HU (1) HUP0300642A3 (fr)
IL (3) IL149138A0 (fr)
LT (1) LT5025B (fr)
LV (1) LV12907B (fr)
MX (1) MXPA02004290A (fr)
MY (2) MY136636A (fr)
NO (1) NO20022086L (fr)
NZ (1) NZ552074A (fr)
PL (1) PL366112A1 (fr)
RO (1) RO123109B1 (fr)
RU (1) RU2276604C2 (fr)
SK (1) SK4992002A3 (fr)
TN (2) TNSN00207A1 (fr)
TW (1) TWI241185B (fr)
UA (2) UA75583C2 (fr)
UY (1) UY26425A1 (fr)
WO (1) WO2001032158A2 (fr)
ZA (2) ZA200203368B (fr)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7235627B2 (en) * 1996-08-30 2007-06-26 Novo Nordisk A/S Derivatives of GLP-1 analogs
US6528486B1 (en) 1999-07-12 2003-03-04 Zealand Pharma A/S Peptide agonists of GLP-1 activity
US6414002B1 (en) 1999-09-22 2002-07-02 Bristol-Myers Squibb Company Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
US20030040469A1 (en) * 2000-03-08 2003-02-27 Knudsen Liselotte Bjerre Lowering serum lipids
EP1283054A4 (fr) * 2000-03-17 2006-04-12 Ajinomoto Kk Medicaments permettant de traiter les complications du diabete et des neuropathies et utilisation de ces medicaments
FR2816840B1 (fr) 2000-11-17 2004-04-09 Flamel Tech Sa Medicament a base de microcapsules d'anti-hyperclycemiant a liberation prolongee et son procede de preparation
US7062312B2 (en) * 2001-01-17 2006-06-13 Pediamed Pharmaceuticals, Inc. Combination and method including a visual marker for determining compliance with a medication regimen
US20020187926A1 (en) * 2001-03-07 2002-12-12 Knudsen Liselotte Bjerre Combined use of derivatives of GLP-1 analogs and PPAR ligands
US20030022816A1 (en) * 2001-03-07 2003-01-30 Knudsen Liselotte Bjerre Combined use of derivatives of GLP-1 analogs and PPAR ligands
FR2825023B1 (fr) * 2001-05-23 2005-04-15 Flamel Tech Sa Forme pharmaceutique orale antidiabetique "une prise par jour"comprenant une biguanide et au moins un autre principe actif
WO2003026637A2 (fr) * 2001-09-28 2003-04-03 Sun Pharmaceutical Industries Limited Forme posologique pour traiter le diabete sucre
US6924311B2 (en) * 2001-10-17 2005-08-02 X-Ceptor Therapeutics, Inc. Methods for affecting various diseases utilizing LXR compounds
US7183321B2 (en) * 2001-12-17 2007-02-27 Bristol-Myers Squibb Company Antidiabetic formulation and method
WO2003061643A1 (fr) * 2002-01-25 2003-07-31 Laboratorios Silanes, S.A. De C.V. Composition pharmaceutique permettant de surveiller le glucose dans le sang de patients souffrant de diabete de type 2
CA2480826C (fr) 2002-04-09 2012-02-07 Flamel Technologies Formulation pharmaceutique orale sous forme de suspension aqueuse de microcapsules permettant la liberation modifiee de principe(s) actif(s)
WO2003105809A1 (fr) 2002-06-17 2003-12-24 Themis Laboratories Private Limited Comprimes multicouche contenant des thiazolidinediones et des biguanides et procedes de production desdits comprimes
WO2004005342A1 (fr) * 2002-07-04 2004-01-15 Zealand Pharma A/S Glp-1 et methodes de traitement du diabete
JP2004067575A (ja) * 2002-08-06 2004-03-04 Yaizu Suisankagaku Industry Co Ltd 糖尿病治療薬効果促進剤
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
SE526943C2 (sv) * 2002-08-26 2005-11-22 Indevex Ab Födoämneskompositionsprodukt
UA80991C2 (en) 2002-10-07 2007-11-26 Solid preparation containing an insulin resistance improving drug and an active ingredient useful as a remedy for diabetes
US20040147564A1 (en) * 2003-01-29 2004-07-29 Rao Vinay U. Combinations of glimepiride and the thiazolidinedione for treatment of diabetes
ATE457166T1 (de) * 2003-07-24 2010-02-15 Wockhardt Ltd Orale zusammensetzungen zur behandlung von diabetes
EP1648933B1 (fr) * 2003-07-25 2009-06-17 ConjuChem Biotechnologies Inc. Derives de l'insuline longue duree et procedes associes
US20050202063A1 (en) * 2003-08-26 2005-09-15 Ebn International Kft Food product
US20050163837A1 (en) * 2003-12-31 2005-07-28 Garth Boehm Rosiglitazone formulations
US20050163842A1 (en) * 2003-12-31 2005-07-28 Garth Boehm Rosiglitazone and metformin formulations
CA2564750A1 (fr) * 2004-04-29 2005-11-17 Andrx Labs, Llc Compositions a base de metformine a liberation regulee
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
US20060188590A1 (en) * 2005-01-05 2006-08-24 Mitsunori Ono Compositions for treating diabetes or obesity
KR20070102694A (ko) * 2005-01-31 2007-10-19 아지노모토 가부시키가이샤 혈당 강하제를 함유하는, 내당능 이상, 경계형 당뇨병,인슐린 저항성 및 고인슐린혈증 개선 또는 치료용 의약조성물
TW200722088A (en) * 2005-05-27 2007-06-16 Sankyo Co Diabetes remedy
BRPI0620718A2 (pt) * 2005-10-28 2011-11-22 Takeda Pharmaceutical agente para a proteção do páncreas, e, uso de uma droga para a redução de glicose
WO2007070355A2 (fr) * 2005-12-09 2007-06-21 Metaproteomics, Llc Produits botaniques anti-inflammatoires pour le traitement du syndrome metabolique et du diabete
FR2896157B1 (fr) * 2006-01-13 2008-09-12 Merck Sante Soc Par Actions Si Combinaison de derives de triazine et d'agents de stimulation de secretion d'insuline.
EP1852108A1 (fr) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG Compositions d'inhibiteurs de la DPP IV
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
CN102838599A (zh) 2006-05-04 2012-12-26 贝林格尔.英格海姆国际有限公司 多晶型
JP2009544630A (ja) * 2006-07-26 2009-12-17 デイアメデイカ・インコーポレイテツド 代謝障害の診断及び治療方法
PE20140960A1 (es) 2008-04-03 2014-08-15 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
US20100136561A1 (en) * 2008-05-16 2010-06-03 Interleukin Genetics, Inc. Genetic Markers for Weight Management and Methods of Use Thereof
BRPI0916997A2 (pt) 2008-08-06 2020-12-15 Boehringer Ingelheim International Gmbh Inibidor de dpp-4 e seu uso
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
KR101189639B1 (ko) * 2008-12-15 2012-10-12 씨제이제일제당 (주) 메트포르민 및 α-글리코시다제 억제제를 포함하는 경구 제제 및 그 제조방법
JP2012522058A (ja) 2009-03-31 2012-09-20 リガンド・ファーマシューティカルズ・インコーポレイテッド 血圧上昇および糖尿病性腎症を処置するための、ジフェニルスルホンアミドエンドセリンおよびアンジオテンシンｉｉ受容体アゴニストの経口製剤
NZ624963A (en) 2009-04-29 2016-07-29 Amarin Pharmaceuticals Ie Ltd Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
BRPI1011876B1 (pt) 2009-04-29 2020-03-31 Amarin Pharma, Inc. Composições farmacêuticas estáveis compreendendo etilácido eicosapentaenoico (etil-epa) e uso das mesmas para tratar ou prevenir uma doença relacionada ao cardiovascular
CN102625847A (zh) 2009-06-15 2012-08-01 阿马里纳制药公司 在相伴他汀类疗法的对象中降低甘油三酯、没有增加ldl-c水平的组合物和方法
US20110009347A1 (en) 2009-07-08 2011-01-13 Yin Liang Combination therapy for the treatment of diabetes
KR102668834B1 (ko) 2009-11-27 2024-05-24 베링거 인겔하임 인터내셔날 게엠베하 리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
CN101810628B (zh) * 2010-04-13 2012-05-23 北京四环科宝制药有限公司 二甲双胍格列吡嗪片及其制备方法
CN107129538B (zh) 2010-04-27 2021-07-16 西兰制药公司 Glp-1受体激动剂和胃泌素的肽缀合物及其用途
ES2935300T3 (es) 2010-05-05 2023-03-03 Boehringer Ingelheim Int Combiterapia
KR101931209B1 (ko) 2010-05-11 2018-12-20 얀센 파마슈티카 엔.브이. Sglt의 억제제로서 1-(베타-d-글루코피라노실)-2-티에닐-메틸벤젠 유도체를 포함하는 약학 제형
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
AU2011336856A1 (en) 2010-11-29 2013-07-04 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
WO2012090225A2 (fr) * 2010-12-29 2012-07-05 Nutracryst Therapeutics Private Limited Nouveaux co-cristaux/sels moléculaires de metformine et d'oléoyléthanolamide utiles en tant qu'agent antidiabétique et antiobésité efficace
MX2013007884A (es) 2011-01-07 2013-09-13 Elcelyx Therapeutics Inc Terapias a base de ligando del receptor quimiosensorial.
US9211263B2 (en) 2012-01-06 2015-12-15 Elcelyx Therapeutics, Inc. Compositions and methods of treating metabolic disorders
US9572784B2 (en) 2011-01-07 2017-02-21 Elcelyx Therapeutics, Inc. Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
US11759441B2 (en) 2011-01-07 2023-09-19 Anji Pharmaceuticals Inc. Biguanide compositions and methods of treating metabolic disorders
US9480663B2 (en) 2011-01-07 2016-11-01 Elcelyx Therapeutics, Inc. Biguanide compositions and methods of treating metabolic disorders
US11974971B2 (en) 2011-01-07 2024-05-07 Anji Pharmaceuticals Inc. Compositions and methods for treating metabolic disorders
US8796338B2 (en) 2011-01-07 2014-08-05 Elcelyx Therapeutics, Inc Biguanide compositions and methods of treating metabolic disorders
WO2013064669A1 (fr) 2011-11-03 2013-05-10 Zealand Pharma A/S Conjugués de peptide agoniste du récepteur du glp-1 et de gastrine
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
KR102231554B1 (ko) 2012-01-06 2021-03-23 앤지 파마 유에스 엘엘씨 대사 장애를 치료하는 조성물 및 방법
KR20200137035A (ko) 2012-01-06 2020-12-08 앤지 파마 유에스 엘엘씨 바이구아나이드 조성물 및 대사 장애를 치료하는 방법
WO2013115742A1 (fr) * 2012-01-31 2013-08-08 Mahmut Bilgic Composition pharmaceutique contenant un inhibiteur de l'alpha-glucosidase
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
WO2013171167A1 (fr) 2012-05-14 2013-11-21 Boehringer Ingelheim International Gmbh Dérivé de xanthine en tant qu'inhibiteur de dpp-4 pour l'utilisation dans le traitement de troubles associés aux podocytes et/ou un syndrome néphrotique
WO2013174767A1 (fr) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh Dérivé de xanthine en tant qu'inhibiteur de la dpp-4 à utiliser dans la modification de l'apport alimentaire et dans la régulation des préférences alimentaires
US20130315891A1 (en) 2012-05-25 2013-11-28 Matthew Charles Formulations of human tissue kallikrein-1 for parenteral delivery and related methods
HUE032613T2 (en) 2012-06-04 2017-10-30 Diamedica Therapeutics Inc Human tissue kallikrein 1 is glycosylated isoforms
AU2013295035B2 (en) 2012-07-23 2017-08-03 Zealand Pharma A/S Glucagon analogues
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
KR101336499B1 (ko) * 2013-03-06 2013-12-03 씨제이제일제당 (주) 당뇨병의 예방 또는 치료용 복합 조성물
US20140271841A1 (en) 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
US9988429B2 (en) 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
RS57632B1 (sr) 2013-10-17 2018-11-30 Zealand Pharma As Acilovani analozi glukagona
AU2014345569B2 (en) 2013-11-06 2020-08-13 Zealand Pharma A/S GIP-GLP-1 dual agonist compounds and methods
EP3066117B1 (fr) 2013-11-06 2019-01-02 Zealand Pharma A/S Composés agonistes triples glucagon-glp-1-gip
ES2950384T3 (es) 2014-02-28 2023-10-09 Boehringer Ingelheim Int Uso médico de un inhibidor de DPP-4
WO2015195662A1 (fr) 2014-06-16 2015-12-23 Amarin Pharmaceuticals Ireland Limited Procédés de réduction ou de prévention de l'oxydation des ldl petites et denses ou des acides gras polyinsaturés membranaires
EP3985016A1 (fr) 2014-10-29 2022-04-20 Zealand Pharma A/S Composés agonistes de gip et procédés associés
EP3283507B8 (fr) 2015-04-16 2019-11-13 Zealand Pharma A/S Analogue acylé du glucagon
EP4233840A3 (fr) 2016-06-10 2023-10-18 Boehringer Ingelheim International GmbH Combinaisons de linagliptine et de metformine
ES2979184T3 (es) 2016-12-09 2024-09-24 Zealand Pharma As Agonistas duales de glp-1/glp-2 acilados
US11857608B2 (en) 2017-03-09 2024-01-02 Diamedica Inc. Dosage forms of tissue kallikrein 1
MA51765A (fr) 2018-09-24 2020-12-16 Amarin Pharmaceuticals Ie Ltd Procédés de réduction du risque d'événements cardiovasculaires chez un sujet
CN113677355A (zh) * 2018-09-24 2021-11-19 潘德勒姆治疗公司 微生物组合物及使用方法
CN113648318B (zh) * 2020-05-12 2023-08-25 中国科学院上海营养与健康研究所 增强细胞产热和治疗疾病的应用
US11986452B2 (en) 2021-04-21 2024-05-21 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of heart failure

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3174901A (en) 1963-01-31 1965-03-23 Jan Marcel Didier Aron Samuel Process for the oral treatment of diabetes
US4060634A (en) 1973-09-26 1977-11-29 Boehringer Mannheim G.M.B.H. Rapidly resorbable glibenclamide
DE2348334C2 (de) 1973-09-26 1982-11-11 Boehringer Mannheim Gmbh, 6800 Mannheim Neue Zubereitungsform des N-4-[2-(5-Chlor-2-methoxybenzamido)äthyl]- phenyl-sulfonyl-N'-cyclohexylharnstoffs
NO154918C (no) 1977-08-27 1987-01-14 Bayer Ag Analogifremgangsmaate til fremstilling av terapeutisk aktive derivater av 3,4,5-trihydroksypiperidin.
EP0062704A1 (fr) 1980-12-03 1982-10-20 Hoechst Aktiengesellschaft Ester d'acides cyclopropancarboxyliques comme agent dans la lutte contre les larves de la famille des gastrophilidae chez les Equidés
JPS6051189A (ja) 1983-08-30 1985-03-22 Sankyo Co Ltd チアゾリジン誘導体およびその製造法
US4916163A (en) 1985-06-04 1990-04-10 The Upjohn Company Spray-dried lactose formulation of micronized glyburide
DE3543999A1 (de) 1985-12-13 1987-06-19 Bayer Ag Hochreine acarbose
US5614492A (en) 1986-05-05 1997-03-25 The General Hospital Corporation Insulinotropic hormone GLP-1 (7-36) and uses thereof
DE3833439A1 (de) 1988-10-01 1991-09-12 Hoechst Ag Verfahren zur mikronisierung von glibenclamid
US5258185A (en) * 1989-08-23 1993-11-02 Bauer Kurt H Highly active, rapidly absorbable formulations of glibenclamide, processes for the production thereof and their use
DK36392D0 (da) 1992-03-19 1992-03-19 Novo Nordisk As Anvendelse af kemisk forbindelse
DE4323636A1 (de) 1993-07-15 1995-01-19 Hoechst Ag Arzneistoffzubereitungen aus umhüllten, schwerstwasserlöslichen Arzneistoffen für Inhalationsarzneiformen und Verfahren zu ihrer Herstellung
TW438587B (en) 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
IT1276130B1 (it) 1995-11-14 1997-10-27 Gentili Ist Spa Associazione glibenclamide-metformina, composizioni farmaceutiche che la contengono e loro uso nel trattamento del diabete mellito di tipo
US6011049A (en) * 1997-02-19 2000-01-04 Warner-Lambert Company Combinations for diabetes
US6153632A (en) 1997-02-24 2000-11-28 Rieveley; Robert B. Method and composition for the treatment of diabetes
CA2290624C (fr) * 1997-06-06 2006-12-05 John W. Shell Formes de dosage de medicaments administres par voie orale a retention gastrique pour liberation lente de medicaments hautement solubles
PT1011673E (pt) 1997-06-13 2001-11-30 Novo Nordisk As Nova posologia para a dmni
WO1998057634A1 (fr) 1997-06-18 1998-12-23 Smithkline Beecham Plc Traitement du diabete a l'aide de thiazolidinedione et de metformine
GB9715306D0 (en) 1997-07-18 1997-09-24 Smithkline Beecham Plc Novel method of treatment
PL344977A1 (en) 1997-10-17 2001-11-19 Aventis Pharm Prod Inc Therapeutic uses of quinoline derivatives
ES2216335T3 (es) 1997-12-08 2004-10-16 Bristol-Myers Squibb Company Nuevas sales de metformina y procedimiento.
FR2774591B1 (fr) 1998-02-12 2000-05-05 Lipha Composition pharmaceutique comprenant l'association metformine et fibrate et son utilisation pour la preparation de medicaments destines a reduire l'hyperglycemie
FI111167B (fi) * 1998-02-24 2003-06-13 Kemira Chemicals Oy Menetelmä lietteen säilyvyyden parantamiseksi
EP1056774A1 (fr) 1998-02-27 2000-12-06 Novo Nordisk A/S Derives de glp-1 tronques a l'extremite n-terminale
EP0974356B1 (fr) 1998-07-15 2003-09-24 Merck Sante Comprimés contenant une combinaison de glibenclamide et de metformine
PL346660A1 (en) 1998-09-17 2002-02-25 Bristol Myers Squibb Co Method for treating atherosclerosis employing an ap2 inhibitor and combination
CO5200844A1 (es) 1999-09-17 2002-09-27 Novartis Ag Una combinacion que comprende nateglinida y cuando por menos otro compuesto antidiabetico usada para el tratamiento de desordenes metabolicos, especialmente diabetes, o de una enfermedad o condicion asociada con dibetes
EP2620443A1 (fr) 2012-01-25 2013-07-31 Galecto Biotech AB Nouveaux inhibiteurs de galectines au galactoside

Also Published As

Publication number Publication date
BG106733A (bg) 2003-02-28
LV12907B (en) 2003-08-20
IL149138A0 (en) 2002-11-10
LT2002062A (en) 2003-03-25
MY125118A (en) 2006-07-31
UY26425A1 (es) 2001-07-31
GEP20053538B (en) 2005-06-10
KR20020050253A (ko) 2002-06-26
RO123109B1 (ro) 2010-11-30
CN101273981B (zh) 2011-01-26
CN100386114C (zh) 2008-05-07
US6586438B2 (en) 2003-07-01
US20020183345A1 (en) 2002-12-05
HUP0300642A2 (hu) 2003-07-28
CN102283853A (zh) 2011-12-21
BG65850B1 (bg) 2010-03-31
CZ304090B6 (cs) 2013-10-16
UA75583C2 (uk) 2006-05-15
RU2276604C2 (ru) 2006-05-20
EP1253944A2 (fr) 2002-11-06
CN101273981A (zh) 2008-10-01
PL366112A1 (en) 2005-01-24
US20020177602A1 (en) 2002-11-28
JP2003529551A (ja) 2003-10-07
TNSN00206A1 (en) 2005-11-10
BR0015295A (pt) 2003-06-24
TNSN00207A1 (en) 2005-11-10
AU8022900A (en) 2001-05-14
DE60038455T2 (de) 2009-04-23
US7598262B2 (en) 2009-10-06
LT5025B (lt) 2003-06-25
RU2002113764A (ru) 2004-03-20
ZA200203367B (en) 2003-09-10
CA2389931A1 (fr) 2001-05-10
HK1045655A1 (zh) 2002-12-06
JP2013028631A (ja) 2013-02-07
WO2001032158A2 (fr) 2001-05-10
KR20020057994A (ko) 2002-07-12
AU781781B2 (en) 2005-06-16
GEP20053539B (en) 2005-06-10
AR026355A1 (es) 2003-02-05
TWI241185B (en) 2005-10-11
NO20022086D0 (no) 2002-05-02
UA76706C2 (uk) 2006-09-15
KR100769786B1 (ko) 2007-10-24
NZ552074A (en) 2008-06-30
MXPA02004290A (es) 2003-02-12
WO2001032158A3 (fr) 2002-08-29
IL149138A (en) 2007-12-03
SK4992002A3 (en) 2003-04-01
ZA200203368B (en) 2003-09-02
HUP0300642A3 (en) 2006-05-29
EE200200241A (et) 2003-12-15
MY136636A (en) 2008-11-28
CN1414862A (zh) 2003-04-30
ES2302702T3 (es) 2008-08-01
CZ20021547A3 (cs) 2003-01-15
BG106732A (bg) 2003-02-28
IL149139A (en) 2011-11-30
DE60038455D1 (de) 2008-05-08
NO20022086L (no) 2002-06-24

Similar Documents

Publication Publication Date Title
EE05210B1 (et) Suhkurt?vevastane preparaat ja selle kasutamine meditsiinis
EE04452B1 (et) Farmatseutiliselt aktiivne morfolinool ja selle kasutamine
EE04144B1 (et) Farmatseutiline kompositsioon ja selle kasutamine
EE05169B1 (et) Asendatud oksasolidinoonid ja nende kasutamine
IL156678A0 (en) Glucopyranosyloxypyrazole derivatives and use thereof in medicines
ID26340A (id) Kapsul ganda dengan penggunaan bahan-bahan aktif dalam berbagai macam pengobatan
EE200100568A (et) 6-alkenüül-, 6-alkünüül- ja 6-epoksüepotilooni derivaadid, nende valmistamismeetod ja kasutamine farmatseutilistes preparaatides
EE200100413A (et) Sünteetilised pindaktiivsed peptiidid ja nende kasutamine sünteetilise surfaktandi valmistamiseks
EE05067B1 (et) Aminoproplfosfiinhapped ning nende kasutamine meditsiinis
EE04565B1 (et) Adamantaani derivaadid, nende saamine ja kasutamine
AU2002225356A1 (en) Glucopyranosyloxypyrazole derivatives and use thereof in medicines
ID22565A (id) Penggunaan nanodispersi dalam formulasi akhir obat
EE200200414A (et) Dihüdro-1,3,5-triasiinamino derivaadid ja nende kasutamine ravis
EE200200484A (et) Väikeseannuseline entekaviiripreparaat ja selle kasutamine
EE200100391A (et) Peptidüül-heterotsüklilised ketoonid, nende kasutamine ja farmatseutiline kompositsioon
PT1212317E (pt) Derivados de indole e sua utilizacao no tratamento de osteoporose entre outras aplicacoes
EE200200160A (et) 2'-asendatud 1,1'-bifenüül-2-karboksamiidid, nende kasutamine ja farmatseutilised preparaadid
DE60022828D1 (de) Kosmetikeinheit und deren Zusammensetzung
FI20000818A0 (fi) Dermatologinen käyttö ja valmiste
EE9900524A (et) N-triasolüül-2-indoolkarboksamiidid ja nende kasutamine CCK-A agonistidena
EE03667B1 (et) Alfa -2 - adrenotseptori antagonisti, selle derivaadi kasutamine ravimi valmistamiseks vaimuhaiguseravimiseks imetajatel ja kompositsioon selle tarvis
EE9900135A (et) N-(2-bensotiasolüül)-1-piperidiinetaanamiini derivaadid, nende valmistamine ja kasutamine raviks
EE200000712A (et) Eeltäidetud süstal ja selle kasutamine
EE200100363A (et) ((Aminoiminometüül)amino)alkaankarboksamiidid ja nende kasutamine ravis
EE200200168A (et) PRV-1-geen ja selle kasutamine

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20101231

MM4A Lapsed by not paying the annual fees

Effective date: 20131013